Under construction – not a live service
Sign in
Taking people in BelgiumPhase 2

Tests imeroprubart in adults with a nerve disorder causing weakness and numbness

Tests imeroprubart against placebo in adults with chronic inflammatory demyelinating polyneuropathy.

Key facts

Who runs it
Immunovant Sciences GmbH
Where
Leuven, BelgiumSee the siteAlso in 29 other countries, 135 sites
Registry title
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Status
Recruiting
Phase
Phase 2
People taking part
162 people, planned
Started
18 Mar 2025
Expected to end
May 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Imeroprubart
  • Placebo
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disease, who are already on steady treatment with corticosteroids or immunoglobulin.

Age
18 years or older
Sex
All sexes can join
Disease stage
Typical CIDP (including incomplete typical CIDP), multifocal CIDP or motor CIDP, with nerve test results that support the diagnosis.
Earlier treatment
Must have been on stable doses of systemic corticosteroids, or immunoglobulin (IVIg or SCIg) with or without corticosteroids, for at least 3 months.
Biomarker or test result
Nerve test (electrodiagnostic) results that support CIDP.

Main reasons for not taking part

  • IgM paraproteinemia, now or in the past
  • Distal, sensory or focal CIDP, or autoimmune nodopathy
  • Nerve disease caused by something other than CIDP
  • Diabetes that is poorly controlled, or without clear typical CIDP and nerve damage on nerve tests
  • History of myelopathy or central demyelination

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Have met clinical diagnostic criteria for typical CIDP (including incomplete typical CIDP) or one of the following CIDP variants: multifocal CIDP or motor CIDP per the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) Guideline on Diagnosis and Treatment of CIDP
  • Have electrodiagnostic test results supporting the diagnosis of CIDP per the EAN/PNS guideline on diagnosis and treatment of CIDP
  • Are currently on, and have been receiving chronic, stable doses of systemic corticosteroids (i.e., daily or every other day oral or pulse regimen), or immunoglobulin therapy (IVIg or SCIg) ± corticosteroid therapy (either low dose oral corticosteroids or pulse corticosteroids) for at least 3 months for the treatment of CIDP at the time of the Screening Visit; Additional inclusion criteria are defined in the protocol

Who cannot take part

  • Have current or prior history of IgM paraproteinemia with or without anti-myelin-associated-glycoprotein antibodies
  • Have distal, sensory, or focal CIDP, or have a diagnosis of autoimmune nodopathy per the EAN/PNS guideline on diagnosis and treatment of CIDP
  • Have polyneuropathy of causes other than CIDP including but not limited to:; Multifocal motor neuropathy; Hereditary demyelinating neuropathy; Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes (i.e., POEMS); Lumbosacral radiculoplexus neuropathy; Systemic illnesses including vitamin deficiency syndromes and paraneoplastic neuropathies; Drug- or toxin-induced
  • Have diabetes mellitus (DM) and meets any of the following criteria:; Does not have both typical CIDP and strong evidence of demyelination on nerve conduction study; In the opinion of the Investigator, there is evidence of poorly controlled DM preceding the diagnosis of CIDP; In the opinion of the Investigator, there is evidence of poorly controlled DM at screening
  • Have a history of myelopathy or evidence of central demyelination. Additional exclusion criteria are defined in the protocol

Where in Belgium

Also in 29 other countries, 135 sites

  • UZ LeuvenLeuven, BelgiumTaking people

About the trial

What the trial wants to find out

This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.

The 2 groups in the trial

  • ImeroprubartTreatment being tested
  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Plain-language title
Tests imeroprubart in adults with a nerve disorder causing weakness and numbnessGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 September 2026